What is the current Veterinary Biological Vaccines market size?

The Veterinary Biological Vaccines market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Veterinary Biological Vaccines market?

Key drivers include rising animal health concerns and growing adoption of veterinary vaccines globally.

What challenges does the Veterinary Biological Vaccines market face?

Challenges include high development costs and strict regulatory requirements for vaccine approval.

Which regions are the leaders in the Veterinary Biological Vaccines market?

North America and Europe are the leading regions, driven by well-established animal healthcare infrastructure.

Who are the top companies in the Veterinary Biological Vaccines market?

Top companies include Zoetis, Merck, and Boehringer Ingelheim, which offer a wide range of veterinary vaccines.

What future opportunities exist in the Veterinary Biological Vaccines market?

Future opportunities include the development of new vaccines for emerging diseases and increasing demand from emerging economies.

How is technology impacting the Veterinary Biological Vaccines market?

Technology is advancing vaccine development, with innovations in genomics and biotechnology improving vaccine efficacy and safety.

What is the current regulatory landscape for the Veterinary Biological Vaccines market?

The regulatory landscape is complex, with strict guidelines from authorities such as the USDA and EMA governing vaccine approval and use.

What is the future outlook for the Veterinary Biological Vaccines market?

The future outlook is positive, with growing demand for veterinary vaccines driving market growth and innovation.

Veterinary Biological Vaccines Market 2026: Primary Research + Expert Analysis

Veterinary Biological Vaccines by Application (Livestock, Swine, Chicken, Others), by Types (Live Attenuated Vaccines, Inactivated Vaccines, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $4500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $4500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Veterinary Biological Vaccines Market Overview

The Veterinary Biological Vaccines market refers to the industry that produces and distributes vaccines for animals to prevent and treat various diseases. The Veterinary Biological Vaccines market size is estimated to be around $8.8 billion in 2025. As the global animal health industry continues to evolve, the Veterinary Biological Vaccines market is expected to experience significant growth outlook, driven by increasing demand for effective and safe vaccines. The market forecast suggests a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033, with the industry expansion being driven by advancements in technology, changing consumer behavior, and rising awareness about animal health. The scope of the market includes various types of vaccines, such as live attenuated vaccines, inactivated vaccines, and recombinant vaccines, which are used to prevent diseases in companion animals and livestock.

Loading chart…

The growth of the Veterinary Biological Vaccines market is driven by several key forces, including technology shifts, such as the development of new vaccine technologies, regulations, such as increasing scrutiny of vaccine safety and efficacy, and consumer behavior, such as increasing awareness about animal health. The largest region for the Veterinary Biological Vaccines market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be shaped by factors such as competitive intensity, supply-chain dynamics, and the emergence of new diseases, which will require the development of new vaccines. As the market continues to evolve, it is essential for industry players to stay informed about the latest trends and developments to remain competitive.

Report Overview

Report Attribute	Details
Market size value in 2025	4.50 billion
Revenue forecast in 2033	7.85 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Zoetis; Boehringer Ingelheim; Ceva; CAHIC; HVRI; Yebio; DHN; WINSUN; Elanco; Virbac; CAVAC; Kyoto Biken Laboratories; FATRO; Vaksindo; Bio-Labs; Avimex Animal Health; MEVAC; Biovac; Atafen; Dyntec; Ringpu Biology; Jinyu Bio-technology; Jinhe Biotechnology; China Animal Husbandry Industry; Wuhan Keqian Biology; Pulike Biological Engineering; Chengdu Kanghua Biological Products
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Veterinary Biological Vaccines market is poised for significant growth, driven by increasing demand for effective disease prevention in animals. The market dynamics are influenced by various factors, including technological advancements, regulatory frameworks, and shifting consumer preferences.

Growth Drivers2 items

Advances in vaccine technology are enabling the development of more effective and targeted vaccines, driving growth in the Veterinary Biological Vaccines market size.

Increasing awareness about animal health and well-being is leading to higher adoption rates of veterinary vaccines, contributing to a positive growth forecast.

Restraints2 items

Stringent regulatory requirements and complex approval processes are limiting the entry of new players in the Veterinary Biological Vaccines market.

High research and development costs associated with vaccine development are hindering the growth of smaller manufacturers and new entrants.

Opportunities2 items

Emerging markets in developing countries present significant opportunities for growth, driven by increasing demand for animal health products and a rising awareness of veterinary vaccines.

The development of novel vaccine platforms and technologies, such as mRNA and viral vector-based vaccines, is expected to drive innovation and growth in the Veterinary Biological Vaccines market.

Challenges2 items

The Veterinary Biological Vaccines market faces challenges related to vaccine safety and efficacy, including the risk of adverse reactions and the potential for vaccine resistance.

Fluctuations in global demand and supply can impact the availability and pricing of veterinary vaccines, affecting the overall growth forecast of the market.

Market Segmentation

Loading chart…

The Application segment of the Veterinary Biological Vaccines market refers to the various uses of these vaccines in preventing and treating diseases in animals. This segment is crucial in understanding the Veterinary Biological Vaccines segmentation, as it helps identify the primary areas where these vaccines are applied. The application segment includes subtypes such as companion animals and livestock, each contributing significantly to the overall market size. For instance, companion animals, including dogs, cats, and horses, require regular vaccinations to prevent diseases such as rabies, distemper, and influenza. On the other hand, livestock, including cattle, pigs, and poultry, require vaccinations to prevent diseases that can lead to significant economic losses.

The Types segment of the Veterinary Biological Vaccines market encompasses various categories of vaccines, including live attenuated vaccines, inactivated vaccines, and subunit vaccines. Each type has its unique characteristics, advantages, and disadvantages, contributing to the overall market taxonomy. Live attenuated vaccines, for example, are weakened forms of the virus or bacteria, providing long-term immunity. Inactivated vaccines, on the other hand, are killed forms of the virus or bacteria, often requiring multiple doses to achieve immunity. Subunit vaccines, which include only specific components of the virus or bacteria, are considered safer and more targeted. Understanding these subtypes is essential in analyzing the market size and growth prospects of the Veterinary Biological Vaccines market.

Veterinary Biological Vaccines Segmentation Breakdown9 items

Application

Livestock

Swine

Chicken

Others

Types

Live Attenuated Vaccines

Inactivated Vaccines

Others

Regional Insights

Loading chart…

The Veterinary Biological Vaccines market growth is anticipated to vary across regions, with the largest share held by North America, accounting for approximately 35% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of veterinary vaccines, favorable government policies, and rising investments in animal healthcare infrastructure.

Key drivers for each region include: North America - established ecosystem maturity, high adoption rates, and significant investments in research and development; Europe - stringent regulatory policies, growing demand for animal-derived products, and increasing focus on animal health; Asia Pacific - rapidly expanding animal healthcare infrastructure, rising awareness about zoonotic diseases, and government initiatives to promote veterinary vaccine adoption; Latin America - growing livestock industry, increasing focus on animal health, and rising demand for veterinary biological vaccines; and Middle East & Africa - growing awareness about animal health, rising investments in veterinary infrastructure, and government initiatives to promote animal healthcare.

The regional forecast indicates that the Asia Pacific region will experience the highest growth rate, driven by factors such as demographics, infrastructure development, and ecosystem maturity. The Latin America and Middle East & Africa regions are also expected to witness significant growth, driven by increasing adoption of veterinary vaccines and rising investments in animal healthcare.

Competitive Landscape

The Veterinary Biological Vaccines market exhibits a moderately consolidated structure, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Veterinary Biological Vaccines competitive landscape is characterized by high competition, with companies employing various strategies to gain a competitive edge. Key competitive levers include product innovation, strategic partnerships, and expansion into new markets.

Companies in the Veterinary Biological Vaccines market employ common strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Merck: regional expansion

Zoetis: innovation pipeline

Boehringer Ingelheim: premium pricing

Ceva: local manufacturing

CAHIC: OEM tie-ups

HVRI: vertical integration

Key Veterinary Biological Vaccines Companies28 items

Merck

Zoetis

Boehringer Ingelheim

Ceva

CAHIC

HVRI

Yebio

DHN

WINSUN

Elanco

Virbac

CAVAC

Kyoto Biken Laboratories

FATRO

Vaksindo

Bio-Labs

Avimex Animal Health

MEVAC

Biovac

Atafen

Dyntec

Ringpu Biology

Jinyu Bio-technology

Jinhe Biotechnology

China Animal Husbandry Industry

Wuhan Keqian Biology

Pulike Biological Engineering

Chengdu Kanghua Biological Products

Market Ecosystem

The Veterinary Biological Vaccines ecosystem encompasses a complex network of participants, from upstream technology providers and raw material suppliers to downstream end users and channels. The ecosystem is structured into three primary segments: upstream, midstream, and downstream, with value creation and capture occurring at each stage. Upstream participants provide critical components and technologies, while midstream integrators and manufacturers develop and produce the vaccines. Downstream channels and end users ultimately receive and utilize the vaccines, driving demand and influencing the overall ecosystem.

Raw material suppliers — provide essential components

Technology providers — develop core vaccine technologies

OEMs / manufacturers — produce veterinary biological vaccines

Distributors / channel partners — deliver vaccines to end users

Regulators/standards bodies — establish vaccine safety and efficacy standards

Service providers / after-sales — offer support and maintenance services

End users / buyers — purchase and administer veterinary biological vaccines

In the Veterinary Biological Vaccines ecosystem, value flows through the interactions and relationships among these participants. Control points, such as regulatory approvals and industry standards, influence adoption and demand. Dependency risks, including input constraints and switching costs, can impact the ecosystem's functioning. As part of a broader value chain analysis, understanding these dynamics is crucial for navigating the complex Veterinary Biological Vaccines ecosystem, which may differ by region due to varying regulatory requirements and market conditions.

Recent Industry Insights

The Veterinary Biological Vaccines industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have driven innovation in vaccine development. Mergers and acquisitions have also been on the rise, with major players expanding their portfolios and strengthening their market presence. Furthermore, several product launches have taken place, introducing new and improved vaccines to the market.

Additionally, regulatory changes have impacted the Veterinary Biological Vaccines industry, with updates to guidelines and standards for vaccine development and approval. Shifts in consumer and enterprise trends have also been observed, with a growing focus on animal health and wellness. Funding rounds and expansions have supported the growth of the industry, enabling companies to invest in research and development and expand their operations. These developments are expected to continue shaping the Veterinary Biological Vaccines industry trends in the future.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Veterinary Biological Vaccines market outlook is that it presents a moderately attractive opportunity, driven by increasing demand for animal health products and a growing focus on disease prevention. The competitive intensity in this market is relatively high, with several established players competing for market share.

The long-term outlook for the Veterinary Biological Vaccines market is positive, with innovation in vaccine technology and rising awareness about animal health expected to drive growth. However, the market is not without risks, including supply chain disruptions and regulatory challenges. The demand-supply balance is currently stable, but may be impacted by factors such as disease outbreaks and changes in government policies.

11 items

1. Executive Summary

2. Veterinary Biological Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Veterinary Biological Vaccines Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Veterinary Biological Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Livestock

6.1.2. Swine

6.1.3. Chicken

6.1.4. Others

6.2. Global Veterinary Biological Vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Live Attenuated Vaccines

6.2.2. Inactivated Vaccines

6.2.3. Others

6.3. Global Veterinary Biological Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Veterinary Biological Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Veterinary Biological Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Veterinary Biological Vaccines Market Competition by Key Manufacturers

8.1. Global Veterinary Biological Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Veterinary Biological Vaccines: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Merck

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Zoetis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Boehringer Ingelheim

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ceva

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. CAHIC

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. HVRI

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Yebio

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. DHN

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. WINSUN

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Elanco

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Virbac

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CAVAC

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Kyoto Biken Laboratories

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. FATRO

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Vaksindo

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Bio-Labs

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Avimex Animal Health

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. MEVAC

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Biovac

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Atafen

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Dyntec

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Ringpu Biology

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Jinyu Bio-technology

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Jinhe Biotechnology

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. China Animal Husbandry Industry

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Wuhan Keqian Biology

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Pulike Biological Engineering

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Chengdu Kanghua Biological Products

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Veterinary Biological Vaccines Market

Figure 4: Global Veterinary Biological Vaccines Market: Drivers

Figure 5: Global Veterinary Biological Vaccines Market: Challenges

Figure 6: Global Veterinary Biological Vaccines Market: Trends

Figure 7: Global Veterinary Biological Vaccines Market: Opportunity

Figure 8: Global Veterinary Biological Vaccines Market: Restraint

Figure 9: Global Veterinary Biological Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Veterinary Biological Vaccines Market Value (USD Million) By Region

Figure 15: Global Veterinary Biological Vaccines Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Veterinary Biological Vaccines Market Value (USD Million) By Region

Figure 23: Global Veterinary Biological Vaccines Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Veterinary Biological Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Veterinary Biological Vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Veterinary Biological Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Veterinary Biological Vaccines Market Value (USD Million) By Region

Table 10: Global Veterinary Biological Vaccines Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Veterinary Biological Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Veterinary Biological Vaccines Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Veterinary Biological Vaccines Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Merck Basic Information And Sales Area

Table 31: Merck. Products Portfolio

Table 32: Zoetis Basic Information And Sales Area

Table 33: Zoetis. Products Portfolio

Table 34: Boehringer Ingelheim Basic Information And Sales Area

Table 35: Boehringer Ingelheim. Products Portfolio

Table 36: Ceva Basic Information And Sales Area

Table 37: Ceva. Products Portfolio

Table 38: CAHIC Basic Information And Sales Area

Table 39: CAHIC. Products Portfolio

Table 40: HVRI Basic Information And Sales Area

Table 41: HVRI. Products Portfolio

Table 42: Yebio Basic Information And Sales Area

Table 43: Yebio. Products Portfolio

Table 44: DHN Basic Information And Sales Area

Table 45: DHN. Products Portfolio

Table 46: WINSUN Basic Information And Sales Area

Table 47: WINSUN. Products Portfolio

Table 48: Elanco Basic Information And Sales Area

Table 49: Elanco. Products Portfolio

Table 50: Virbac Basic Information And Sales Area

Table 51: Virbac. Products Portfolio

Table 52: CAVAC Basic Information And Sales Area

Table 53: CAVAC. Products Portfolio

Table 54: Kyoto Biken Laboratories Basic Information And Sales Area

Table 55: Kyoto Biken Laboratories. Products Portfolio

Table 56: FATRO Basic Information And Sales Area

Table 57: FATRO. Products Portfolio

Table 58: Vaksindo Basic Information And Sales Area

Table 59: Vaksindo. Products Portfolio

Table 60: Bio-Labs Basic Information And Sales Area

Table 61: Bio-Labs. Products Portfolio

Table 62: Avimex Animal Health Basic Information And Sales Area

Table 63: Avimex Animal Health. Products Portfolio

Table 64: MEVAC Basic Information And Sales Area

Table 65: MEVAC. Products Portfolio

Table 66: Biovac Basic Information And Sales Area

Table 67: Biovac. Products Portfolio

Table 68: Atafen Basic Information And Sales Area

Table 69: Atafen. Products Portfolio

Table 70: Dyntec Basic Information And Sales Area

Table 71: Dyntec. Products Portfolio

Table 72: Ringpu Biology Basic Information And Sales Area

Table 73: Ringpu Biology. Products Portfolio

Table 74: Jinyu Bio-technology Basic Information And Sales Area

Table 75: Jinyu Bio-technology. Products Portfolio

Table 76: Jinhe Biotechnology Basic Information And Sales Area

Table 77: Jinhe Biotechnology. Products Portfolio

Table 78: China Animal Husbandry Industry Basic Information And Sales Area

Table 79: China Animal Husbandry Industry. Products Portfolio

Table 80: Wuhan Keqian Biology Basic Information And Sales Area

Table 81: Wuhan Keqian Biology. Products Portfolio

Table 82: Pulike Biological Engineering Basic Information And Sales Area

Table 83: Pulike Biological Engineering. Products Portfolio

Table 84: Chengdu Kanghua Biological Products Basic Information And Sales Area

Table 85: Chengdu Kanghua Biological Products. Products Portfolio

Table 86: Global Market Value (USD Million) (2025-2032) By Application

Table 87: Global Market Share (%) By Application (2032)

Table 88: Global Market Value (USD Million) (2025-2032) By Types

Table 89: Global Market Share (%) By Types (2032)

Table 90: Global Veterinary Biological Vaccines Market Value (USD Million) By Region

Table 91: Global Veterinary Biological Vaccines Market Share (%) By Region (2025-2032)

Table 92: North America Market Value (USD Million) (2025-2032) By Country

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: North America Market Value (USD Million) (2025-2032) By Types

Table 95: Europe Market Value (USD Million) (2025-2032) By Country

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Europe Market Value (USD Million) (2025-2032) By Types

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 101: South America Market Value (USD Million) (2025-2032) By Country

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: South America Market Value (USD Million) (2025-2032) By Types

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Veterinary Biological Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.50 billion
Revenue forecast in 2033	7.85 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Zoetis; Boehringer Ingelheim; Ceva; CAHIC; HVRI; Yebio; DHN; WINSUN; Elanco; Virbac; CAVAC; Kyoto Biken Laboratories; FATRO; Vaksindo; Bio-Labs; Avimex Animal Health; MEVAC; Biovac; Atafen; Dyntec; Ringpu Biology; Jinyu Bio-technology; Jinhe Biotechnology; China Animal Husbandry Industry; Wuhan Keqian Biology; Pulike Biological Engineering; Chengdu Kanghua Biological Products
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in vaccine technology are enabling the development of more effective and targeted vaccines, driving growth in the Veterinary Biological Vaccines market size.

Increasing awareness about animal health and well-being is leading to higher adoption rates of veterinary vaccines, contributing to a positive growth forecast.

Restraints2 items

Stringent regulatory requirements and complex approval processes are limiting the entry of new players in the Veterinary Biological Vaccines market.

High research and development costs associated with vaccine development are hindering the growth of smaller manufacturers and new entrants.

Opportunities2 items

Emerging markets in developing countries present significant opportunities for growth, driven by increasing demand for animal health products and a rising awareness of veterinary vaccines.

Challenges2 items

The Veterinary Biological Vaccines market faces challenges related to vaccine safety and efficacy, including the risk of adverse reactions and the potential for vaccine resistance.

Fluctuations in global demand and supply can impact the availability and pricing of veterinary vaccines, affecting the overall growth forecast of the market.

Market Segmentation

Loading chart…

Veterinary Biological Vaccines Segmentation Breakdown9 items

Application

Livestock

Swine

Chicken

Others

Types

Live Attenuated Vaccines

Inactivated Vaccines

Others

Regional Insights

Loading chart…

Competitive Landscape

Merck: regional expansion

Zoetis: innovation pipeline

Boehringer Ingelheim: premium pricing

Ceva: local manufacturing

CAHIC: OEM tie-ups

HVRI: vertical integration

Key Veterinary Biological Vaccines Companies28 items

Merck

Zoetis

Boehringer Ingelheim

Ceva

CAHIC

HVRI

Yebio

DHN

WINSUN

Elanco

Virbac

CAVAC

Kyoto Biken Laboratories

FATRO

Vaksindo

Bio-Labs

Avimex Animal Health

MEVAC

Biovac

Atafen

Dyntec

Ringpu Biology

Jinyu Bio-technology

Jinhe Biotechnology

China Animal Husbandry Industry

Wuhan Keqian Biology

Pulike Biological Engineering

Chengdu Kanghua Biological Products

Market Ecosystem

Raw material suppliers — provide essential components

Technology providers — develop core vaccine technologies

OEMs / manufacturers — produce veterinary biological vaccines

Distributors / channel partners — deliver vaccines to end users

Regulators/standards bodies — establish vaccine safety and efficacy standards

Service providers / after-sales — offer support and maintenance services

End users / buyers — purchase and administer veterinary biological vaccines

Recent Industry Insights

Analyst Overview

Table of Contents